The fact that Dr. Lalezari doesn't own shares, adds to the creditability of his glowing assessment of Leronlimab. While he did admit to a positive bias, it seemed to be based on his experience with Leronlimab in past and present Trials. The question about whether someone reached out to Dr. Fauci was not actually answered, but I would be shocked if it did not happen. I believe Dr. Lalezari has been an important Trial contributor and is well thought of by FDA opinion leaders.